Video Experimental Relacionado
Updated: Jun 3, 2026
06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
Las clusterinas plasmáticas y el riesgo de enfermedad de Alzheimer
Elisabeth M C Schrijvers1, Peter J Koudstaal, Albert Hofman
1Department of Epidemiology, Erasmus MC University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands.
JAMA
|April 7, 2011
Resumen
Los niveles plasmáticos de clusterina están relacionados con la presencia y la gravedad de la enfermedad de Alzheimer (EA). Sin embargo, este estudio no encontró ninguna asociación entre la clusterina plasmática y el riesgo de desarrollar AD con el tiempo.
Área de la Ciencia:
- La neurociencia es la neurociencia.
- Investigación de biomarcadores Investigación de biomarcadores.
- Genética La genética.
Sus antecedentes:
- Las variantes genéticas de la clusterina están asociadas con el riesgo de enfermedad de Alzheimer (EA).
- Se observan niveles elevados de clusterina en el cerebro y el líquido cefalorraquídeo de pacientes con EA.
- La clusterina plasmática se correlaciona con la atrofia cerebral, la gravedad de la enfermedad y la progresión en la enfermedad de Alzheimer.
Objetivo del estudio:
- Investigar la clusterina plasmática como un biomarcador potencial para la enfermedad de Alzheimer.
- Evaluar su utilidad en la identificación de la presencia, gravedad y riesgo de AD.
Principales métodos:
- Un estudio de caso-cohorte dentro del estudio prospectivo de Rotterdam.
- Niveles plasmáticos de clusterin medidos en participantes con AD prevalente, una subcohorte aleatoria y casos incidentes de AD.
- Seguimiento hasta el 1 de enero de 2007, con el diagnóstico de EA y las puntuaciones del Mini-Mental State Examination (MMSE) registradas.
Principales resultados:
- El aumento de los niveles plasmáticos de clusterina se correlacionó con una mayor probabilidad de prevalencia de AD.
- Los niveles más altos de clusterina se asociaron con una enfermedad de Alzheimer más grave, indicada por puntuaciones MMSE más bajas.
- La clusterina plasmática no se relacionó significativamente con el riesgo de AD incidente durante el período de seguimiento.
Conclusiones:
- La clusterina plasmática se asocia con la prevalencia y la gravedad de la enfermedad de Alzheimer al inicio.
- La clusterina plasmática no parece ser un predictor confiable para la incidencia de la enfermedad de Alzheimer.
Más Videos Relacionados
09:33Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
04:22Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles
Published on: May 20, 2024
Videos de Conceptos Relacionados
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...